Kidney Insufficiency Clinical Trial
Official title:
Pilot Study of Rituximab Treatment to Inhibit HLA Antibodies in Renal Allograft Recipients
The purpose of this study is to determine if administration of rituximab blocks the development of donor specific antibodies (DSA) in transplant recipients who have developed renal dysfunction and DSA after renal transplant. It is hoped that by blocking DSA production renal function will stabilize or improve.
A long established risk factor for late renal allograft loss is the development of DSA. Recent studies from our group and others have shown that these antibodies are probably responsible for chronic rejection by attacking the vascular endothelium and fixing complement (detected as C4d in renal biopsies). Studies in humans and monkeys have shown that circulating antibody and complement deposition precede the development of chronic graft injury. Interruption of antibody production is a potential beneficial strategy to prevent late graft loss from this mechanism. Therapeutic regimens that have been used in an attempt to deplete HLA or ABO antibodies include plasmapheresis, IVIg, tacrolimus and mycophenolate mofetil (MMF), and anti-CD20 (rituximab). Of these regimens, the most specific is anti-CD20, rituximab (rituxan), a therapy now FDA approved for B cell proliferative diseases. Although initially introduced for the treatment of neoplasm, the humoral immunosuppressant effects of rituximab have been shown to have clinical significance. Rituximab interferes with both primary and secondary humoral responses by eliminating B-cells prior to antigen exposure, thus interfering with differentiation into antibody secreting cells and specific antibody production. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Completed |
NCT02964429 -
Determination In-vivo KUF for Diacap Pro Hemodialyser
|
N/A | |
Recruiting |
NCT04485845 -
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
|
Phase 4 | |
Completed |
NCT01083849 -
Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice
|
N/A | |
Withdrawn |
NCT00476515 -
Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor
|
Phase 1 | |
Completed |
NCT04594161 -
Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis
|
N/A | |
Terminated |
NCT04626427 -
The WavelinQâ„¢ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation
|
N/A | |
Recruiting |
NCT04058951 -
Plant Versus Animal Dietary Protein and the Effect on Proteinuria
|
N/A |